These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 26571205)

  • 1. Immunomodulation as a neuroprotective and therapeutic strategy for Parkinson's disease.
    Olson KE; Gendelman HE
    Curr Opin Pharmacol; 2016 Feb; 26():87-95. PubMed ID: 26571205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunomodulation of Parkinson's disease using Mucuna pruriens (Mp).
    Rai SN; Birla H; Zahra W; Singh SS; Singh SP
    J Chem Neuroanat; 2017 Nov; 85():27-35. PubMed ID: 28642128
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Linking Neuroinflammation and Neurodegeneration in Parkinson's Disease.
    Gelders G; Baekelandt V; Van der Perren A
    J Immunol Res; 2018; 2018():4784268. PubMed ID: 29850629
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroprotection and neurorestoration as experimental therapeutics for Parkinson's disease.
    Francardo V; Schmitz Y; Sulzer D; Cenci MA
    Exp Neurol; 2017 Dec; 298(Pt B):137-147. PubMed ID: 28988910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of animal models of Parkinson's disease for neuroprotective strategies.
    Emborg ME
    J Neurosci Methods; 2004 Oct; 139(2):121-43. PubMed ID: 15488225
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Designing neuroprotection trials in Parkinson's disease.
    Kieburtz K
    Ann Neurol; 2003; 53 Suppl 3():S100-7; discussion S107-9. PubMed ID: 12666102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Beta-asarone protects against MPTP-induced Parkinson's disease via regulating long non-coding RNA MALAT1 and inhibiting α-synuclein protein expression.
    Zhang QS; Wang ZH; Zhang JL; Duan YL; Li GF; Zheng DL
    Biomed Pharmacother; 2016 Oct; 83():153-159. PubMed ID: 27470562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. α-Synuclein vaccination modulates regulatory T cell activation and microglia in the absence of brain pathology.
    Christiansen JR; Olesen MN; Otzen DE; Romero-Ramos M; Sanchez-Guajardo V
    J Neuroinflammation; 2016 Apr; 13(1):74. PubMed ID: 27055651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neuroprotection in Parkinson's disease: clinical trials.
    Stocchi F; Olanow CW
    Ann Neurol; 2003; 53 Suppl 3():S87-97; discussion S97-9. PubMed ID: 12666101
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to judge animal models of Parkinson's disease in terms of neuroprotection.
    Hirsch EC
    J Neural Transm Suppl; 2006; (70):255-60. PubMed ID: 17017538
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neuroprotection in Parkinson's disease: an elusive goal.
    Biglan KM; Ravina B
    Semin Neurol; 2007 Apr; 27(2):106-12. PubMed ID: 17390255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.
    Perez-Lloret S; Otero-Losada M; Toblli JE; Capani F
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1163-1173. PubMed ID: 28836869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neuroprotective mechanisms of plant extracts against MPTP induced neurotoxicity: Future applications in Parkinson's disease.
    Abushouk AI; Negida A; Ahmed H; Abdel-Daim MM
    Biomed Pharmacother; 2017 Jan; 85():635-645. PubMed ID: 27890431
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuroprotective activities of CD4+CD25+ regulatory T cells in an animal model of Parkinson's disease.
    Reynolds AD; Banerjee R; Liu J; Gendelman HE; Mosley RL
    J Leukoc Biol; 2007 Nov; 82(5):1083-94. PubMed ID: 17675560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autoimmunity in Parkinson's Disease: The Role of α-Synuclein-Specific T Cells.
    Garretti F; Agalliu D; Lindestam Arlehamn CS; Sette A; Sulzer D
    Front Immunol; 2019; 10():303. PubMed ID: 30858851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Neuroprotection in Parkinson's disease: analysis though group of experts' methodology].
    Linazasoro G; Sesar A; Valldeoriola F; Compta Y; Herrero MT; Martínez Castrillo JC; López Lozano JJ; Bergaretxe A; Vela L; Fernández JM; Castro A; Kulisevski J; Lezcano E; Vaamonde J; López Del Val J; Chacón J; Vivancos F; Luquin R; Aguilar M; Burguera JA; Salvador C; Menéndez Guisasola L; Catalán MJ; Mir P; Campos V; Grandas F; Mínguez A; Balaguer E; Yáñez R; Leiva C; García Ruiz P; Cubo E
    Neurologia; 2009 Mar; 24(2):113-24. PubMed ID: 19322690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough.
    Löhle M; Reichmann H
    J Neurol Sci; 2010 Feb; 289(1-2):104-14. PubMed ID: 19772974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disease-Modifying Drugs in Parkinson's Disease.
    Park A; Stacy M
    Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The key role of T cells in Parkinson's disease pathogenesis and therapy.
    Baird JK; Bourdette D; Meshul CK; Quinn JF
    Parkinsonism Relat Disord; 2019 Mar; 60():25-31. PubMed ID: 30404763
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drugs to prevent cell death in Parkinson's disease. Neuroprotection against oxidative stress and inflammatory gene expression.
    Youdim MB; Grünblatt E; Levites-Royak Y; Mandel S
    Adv Neurol; 2001; 86():115-24. PubMed ID: 11553968
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.